Cargando…
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF)...
Autor principal: | Nessler, Jadwiga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356825/ https://www.ncbi.nlm.nih.gov/pubmed/34400915 http://dx.doi.org/10.5114/aic.2021.107491 |
Ejemplares similares
-
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021) -
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021) -
Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022) -
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021) -
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)